Design Therapeutics Inc
DSGN9.630USD
-0.110-1.13%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
548.56MMarket Cap
LossP/E TTM
More Details of Design Therapeutics Inc Company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Design Therapeutics Inc Info
Ticker SymbolDSGN
Company nameDesign Therapeutics Inc
IPO dateMar 26, 2021
CEOShah (Pratik)
Number of employees54
Security typeOrdinary Share
Fiscal year-endMar 26
Address6005 Hidden Valley Road
CityCARLSBAD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92011
Phone18582934900
Websitehttps://www.designtx.com/
Ticker SymbolDSGN
IPO dateMar 26, 2021
CEOShah (Pratik)
Company Executives of Design Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Christopher M. (Chris) Storgard, M.D.
Dr. Christopher M. (Chris) Storgard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ansari (Aseem Z. Ph.D.)
13.46%
SR One Capital Management, LP
11.46%
Quan Venture Fund II LP
7.02%
Light Irrevocable Trust.
6.73%
Star Irrevocable Trust.
6.73%
Other
54.60%
Shareholders
Shareholders
Proportion
Ansari (Aseem Z. Ph.D.)
13.46%
SR One Capital Management, LP
11.46%
Quan Venture Fund II LP
7.02%
Light Irrevocable Trust.
6.73%
Star Irrevocable Trust.
6.73%
Other
54.60%
Shareholder Types
Shareholders
Proportion
Corporation
20.48%
Hedge Fund
17.43%
Venture Capital
16.70%
Individual Investor
15.49%
Investment Advisor
12.62%
Investment Advisor/Hedge Fund
8.16%
Private Equity
3.43%
Research Firm
0.49%
Pension Fund
0.09%
Other
5.11%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
201
33.55M
67.46%
-1.14M
2025Q3
210
34.69M
75.59%
-1.21M
2025Q2
225
34.76M
96.59%
+71.45K
2025Q1
235
34.68M
94.36%
-18.89M
2024Q4
250
33.68M
92.48%
+1.46M
2024Q3
257
32.21M
90.35%
+726.66K
2024Q2
256
32.25M
93.39%
+1.36M
2024Q1
255
30.89M
94.73%
-22.63M
2023Q4
245
32.10M
91.67%
-1.34M
2023Q3
236
33.36M
78.54%
-6.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ansari (Aseem Z. Ph.D.)
7.67M
13.47%
--
--
Mar 31, 2025
SR One Capital Management, LP
6.53M
11.46%
--
--
Jun 30, 2025
Quan Venture Fund II LP
4.00M
7.02%
-133.00K
-3.22%
Mar 31, 2025
Light Irrevocable Trust.
3.83M
6.73%
--
--
Mar 31, 2025
Star Irrevocable Trust.
3.83M
6.73%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.94M
5.17%
+1.14M
+62.83%
Aug 27, 2025
Logos Global Management LP
4.22M
7.41%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.95M
3.43%
--
--
Jun 30, 2025
Tang Capital Management, LLC
1.78M
3.13%
+100.00K
+5.95%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.10M
3.68%
-105.28K
-4.78%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
Fidelity Enhanced Small Cap ETF
Proportion0.04%
iShares Micro-Cap ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Design Therapeutics Inc?
The top five shareholders of Design Therapeutics Inc are:
Ansari (Aseem Z. Ph.D.) holds 7.67M shares, accounting for 13.47% of the total shares.
SR One Capital Management, LP holds 6.53M shares, accounting for 11.46% of the total shares.
Quan Venture Fund II LP holds 4.00M shares, accounting for 7.02% of the total shares.
Light Irrevocable Trust. holds 3.83M shares, accounting for 6.73% of the total shares.
Star Irrevocable Trust. holds 3.83M shares, accounting for 6.73% of the total shares.
Ansari (Aseem Z. Ph.D.) holds 7.67M shares, accounting for 13.47% of the total shares.
SR One Capital Management, LP holds 6.53M shares, accounting for 11.46% of the total shares.
Quan Venture Fund II LP holds 4.00M shares, accounting for 7.02% of the total shares.
Light Irrevocable Trust. holds 3.83M shares, accounting for 6.73% of the total shares.
Star Irrevocable Trust. holds 3.83M shares, accounting for 6.73% of the total shares.
What are the top three shareholder types of Design Therapeutics Inc?
The top three shareholder types of Design Therapeutics Inc are:
Ansari (Aseem Z. Ph.D.)
SR One Capital Management, LP
Quan Venture Fund II LP
Ansari (Aseem Z. Ph.D.)
SR One Capital Management, LP
Quan Venture Fund II LP
How many institutions hold shares of Design Therapeutics Inc (DSGN)?
As of 2025Q4, 201 institutions hold shares of Design Therapeutics Inc, with a combined market value of approximately 33.55M, accounting for 67.46% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -8.13%.
What is the biggest source of revenue for Design Therapeutics Inc?
In --, the -- business generated the highest revenue for Design Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
